ArticlemBio2014
Enhanced specialized transduction using recombineering in Mycobacterium tuberculosis.
Article in mBio, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- Construction and characterization of novelInfection and immunity · 2026Article
- Uncovering Insights Into the Biology of Mycobacterium tuberculosis Using Genetic Tools.MicrobiologyOpen · 2025Review
- Review of the Presence and Phage-Mediated Transfer of ARGs in Biofilms.Microorganisms · 2025Review
- A CRISPR-nonhomologous end-joining-based strategy for rapid and efficient gene disruption inmLife · 2025Article
- CRISPR/Cas12a-mediated gene silencing across diverse functional genes demonstrates single gene-specific spacer efficacy in Mycobacterium smegmatis.Journal of biological engineering · 2025Article
- The small non-coding RNA B11 regulates multiple facets of Mycobacterium abscessus virulence.PLoS pathogens · 2023Article
- Mycobacteriophages in diagnosis and alternative treatment of mycobacterial infections.Frontiers in microbiology · 2023Review
- Mycobacteriophages: From Petri dish to patient.PLoS pathogens · 2022Review
- An amiloride derivative is active against the FCommunications biology · 2022Article
- Article
- Oligo-Mediated Recombineering and its Use for Making SNPs, Knockouts, Insertions, and Fusions in Mycobacterium tuberculosis.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Article
- The Biotin Biosynthetic Pathway in Mycobacterium tuberculosis is a Validated Target for the Development of Antibacterial Agents.Current medicinal chemistry · 2020Review
- Handling the Hurdles on the Way to Anti-tuberculosis Drug Development.Frontiers in chemistry · 2020Review
- Targeting the Serine Pathway: A Promising Approach against Tuberculosis?Pharmaceuticals (Basel, Switzerland) · 2019Article
- Mycobacteriophage ZoeJ: A broad host-range close relative of mycobacteriophage TM4.Tuberculosis (Edinburgh, Scotland) · 2019Article
- Cell envelope stress in mycobacteria is regulated by the novel signal transduction ATPase IniR in response to trehalose.PLoS genetics · 2017Article
- Post-translational Acetylation of MbtA Modulates Mycobacterial Siderophore Biosynthesis.The Journal of biological chemistry · 2016Article
- Investigating essential gene function in Mycobacterium tuberculosis using an efficient CRISPR interference system.Nucleic acids research · 2016Article
- Network analysis identifies Rv0324 and Rv0880 as regulators of bedaquiline tolerance in Mycobacterium tuberculosis.Nature microbiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
unlabelledG: enetic engineering has contributed greatly to our understanding of Mycobacterium tuberculosis biology and has facilitated antimycobacterial and vaccine development. However, methods to generate M. tuberculosis deletion mutants remain labor-intensive and relatively inefficient. Here, methods are described that significantly enhance the efficiency (greater than 100-fold) of recovering deletion mutants by the expression of mycobacteriophage recombineering functions during the course of infection with specialized transducing phages delivering allelic exchange substrates. This system has been successfully applied to the CDC1551 strain of M. tuberculosis, as well as to a ΔrecD mutant generated in the CDC1551 parental strain. The latter studies were undertaken as there were precedents in both the Escherichia coli literature and mycobacterial literature for enhancement of homologous recombination in strains lacking RecD. In combination, these measures yielded a dramatic increase in the recovery of deletion mutants and are expected to facilitate construction of a comprehensive library of mutants with every nonessential gene of M. tuberculosis deleted. The findings also open up the potential for sophisticated genetic screens, such as synthetic lethal analyses, which have so far not been feasible for the slow-growing mycobacteria. IMPORTANCE: Genetic manipulation of M. tuberculosis is hampered by laborious and relatively inefficient methods for generating deletion mutant strains. The combined use of phage-based transduction and recombineering methods greatly enhances the efficiency by which knockout strains can be generated. The additional elimination of recD further enhances this efficiency. The methods described herein will facilitate the construction of comprehensive gene knockout libraries and expedite the isolation of previously difficult to recover mutants, promoting antimicrobial and vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.